Institutional shares held 40.8 Million
63.1K calls
420K puts
Total value of holdings $1.33B
$2.05M calls
$13.7M puts
Market Cap $3.08B
97,908,704 Shares Out.
Institutional ownership 41.69%
# of Institutions 116


Latest Institutional Activity in ZLAB

Top Purchases

Q3 2024
Hennion & Walsh Asset Management, Inc. Shares Held: 142K ($4.47M)
Q3 2024
Deka Bank Deutsche Girozentrale Shares Held: 36.6K ($1.15M)
Q3 2024
China Universal Asset Management Co., Ltd. Shares Held: 9.56K ($300K)
Q3 2024
Allspring Global Investments Holdings, LLC Shares Held: 430 ($13.5K)
Q3 2024
Ronald Blue Trust, Inc. Shares Held: 241 ($7.57K)

Top Sells

Q3 2024
Mirae Asset Global Investments Co., Ltd. Shares Held: 4.52K ($142K)
Q3 2024
Cwm, LLC Shares Held: 446 ($14K)
Q3 2024
Farther Finance Advisors, LLC Shares Held: 134 ($4.21K)
Q3 2024
Us Bancorp \De\ Shares Held: 331 ($10.4K)
Q2 2024
Legal & General Group PLC Shares Held: 210K ($6.59M)

About ZLAB

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.


Insider Transactions at ZLAB

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
482K Shares
From 15 Insiders
Exercise of conversion of derivative security 297K shares
Open market or private purchase 15K shares
Grant, award, or other acquisition 170K shares
Sell / Disposition
267K Shares
From 9 Insiders
Open market or private sale 146K shares
Bona fide gift 122K shares

Track Institutional and Insider Activities on ZLAB

Follow Zai Lab Ltd and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ZLAB shares.

Notify only if

Insider Trading

Get notified when an Zai Lab LTD insider buys or sells ZLAB shares.

Notify only if

News

Receive news related to Zai Lab Ltd

Track Activities on ZLAB